Che

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject
to Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(h)

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL 3235-0287 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* SIMARD JOHN						2. Issuer Name and Ticker or Trading Symbol XBiotech Inc. [XBIT]													wner	
(Last) (First) (Middle) 5217 WINNEBAGO LANE						3. Date of Earliest Transaction (Month/Day/Year) 10/07/2021									Officer (give title below) Chief Executive Officer				specify	
(Street) AUSTIN TX 78744					4. 1	4. If Amendment, Date of Original Filed (Month/Day/Year)									ridual or Joint/Group Filing (Check Applicable Form filed by One Reporting Person Form filed by More than One Reporting					
(City)	(City) (State) (Zip)														Person					
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																				
				2. Transaction Date (Month/Day/Year)		2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr. 8)		ion	4. Securities Acquired Disposed Of (D) (Instr.					Securities Beneficially Owned Following		n: Direct or rect (I)	7. Nature of Indirect Beneficial Ownership	
								Cod	e V	/	Amount	(A) or (D)	Price		Transa	ction(s) 3 and 4)	(Inst	ır. 4)	(Instr. 4)	
Common Stock 10/07/					1			S	S		39,286	D	\$12.45 ⁽¹⁾		3,923,166			D		
Common Stock				10/12/202	1						18,000	D	\$12.7	744(1)	3,9	3,973,166		D		
Common Stock 10/13/2				10/13/202	1			S			10,875	D	\$12.	.83(1)	3,962,452			D		
Common Stock 10/14/202					1			S			21,125	D	\$12.9005 ⁽¹⁾		3,873,166			D		
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
Security or Exercise (Month/Day/Year) if any			ution Date, Tra		saction e (Instr.	5. Numb of Derivati Securiti Acquire (A) or Dispose of (D) (Instr. 3, and 5)	ve (fes d	Expiration (Month/Da			Amo Secu Unde Deriv	le and unt of irities erlying vative irity (Ins	Deri Sec (Ins	rice of ivative urity tr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	,	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
					Code	e V	(A) (E		Date Exerci	isabl	Expiration e Date	n Title	Amou or Numb of Share	er						

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions. The reporting person undertakes to provide to XBIT, any security holder of XBIT, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

John Simard, CEO Chairman of XBiotech, Inc., adopted a stock trading plan. He sold total of 89,286 common stock on the open market as part of this 10B5-1 trading plan.

/s/ Queena Han under Power of Attorney for John Simard

10/15/2021

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.